Literature DB >> 15890588

Penile brachytherapy: results for 49 patients.

Juanita M Crook1, John Jezioranski, Laval Grimard, Bernd Esche, G Pond.   

Abstract

PURPOSE: To report results for 49 men with squamous cell carcinoma (SCC) of the penis treated with primary penile interstitial brachytherapy at one of two institutions: the Ottawa Regional Cancer Center, Ottawa, and the Princess Margaret Hospital, Toronto, Ontario, Canada. METHODS AND MATERIALS: From September 1989 to September 2003, 49 men (mean age, 58 years; range, 22-93 years) had brachytherapy for penile SCC. Fifty-one percent of tumors were T1, 33% T2, and 8% T3; 4% were in situ and 4% Tx. Grade was well differentiated in 31%, moderate in 45%, and poor in 2%; grade was unspecified for 20%. One tumor was verrucous. All tumors in Toronto had pulsed dose rate (PDR) brachytherapy (n = 23), whereas those in Ottawa had either Iridium wire (n = 22) or seeds (n = 4). Four patients had a single plane implant with a plastic tube technique, and all others had a volume implant with predrilled acrylic templates and two or three parallel planes of needles (median, six needles). Mean needle spacing was 13.5 mm (range, 10-18 mm), mean dose rate was 65 cGy/h (range, 33-160 cGy/h), and mean duration was 98.8 h (range, 36-188 h). Dose rates for PDR brachytherapy were 50-61.2 cGy/h, with no correction in total dose, which was 60 Gy in all cases.
RESULTS: Median follow-up was 33.4 months (range, 4-140 months). At 5 years, actuarial overall survival was 78.3% and cause-specific survival 90.0%. Four men died of penile cancer, and 6 died of other causes with no evidence of recurrence. The cumulative incidence rate for never having experienced any type of failure at 5 years was 64.4% and for local failure was 85.3%. All 5 patients with local failure were successfully salvaged by surgery; 2 other men required penectomy for necrosis. The soft tissue necrosis rate was 16% and the urethral stenosis rate 12%. Of 8 men with regional failure, 5 were salvaged by lymph node dissection with or without external radiation. All 4 men with distant failure died of disease. Of 49 men, 42 had an intact and tumor-free penis at last follow-up or death. The actuarial penile preservation rate at 5 years was 86.5%.
CONCLUSIONS: Brachytherapy is an effective treatment for T1, T2, and selected T3 SCC of the penis. Close follow-up is mandatory because local failures and many regional failures can be salvaged by surgery.

Entities:  

Mesh:

Year:  2005        PMID: 15890588     DOI: 10.1016/j.ijrobp.2004.10.016

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

Review 1.  A review of the clinical experience in pulsed dose rate brachytherapy.

Authors:  Brian V Balgobind; Kees Koedooder; Diego Ordoñez Zúñiga; Raquel Dávila Fajardo; Coen R N Rasch; Bradley R Pieters
Journal:  Br J Radiol       Date:  2015-08-20       Impact factor: 3.039

Review 2.  Advanced penile cancer.

Authors:  Jonathan E Heinlen; David D Buethe; Daniel Joseph Culkin
Journal:  Int Urol Nephrol       Date:  2011-08-04       Impact factor: 2.370

3.  Organ-sparing treatment of penile cancer with interstitial pulsed-dose-rate brachytherapy.

Authors:  Johannes Seibold; Vratislav Strnad; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2016-06-09       Impact factor: 3.621

4.  Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).

Authors:  Suzanne Richter; J Dean Ruether; Lori Wood; Christina Canil; Patricia Moretto; Peter Venner; Joel Gingerich; Urban Emmenegger; Andrea Eisen; Pawel Zalewski; Anthony Joshua; Som Dave Mukherjee; Daniel Heng; Piotr Czaykowski; Denis Soulieres; Norman Blais; Ricardo Rendon; Neil Fleshner; Juanita M Crook; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

5.  Neonatal circumcision and invasive squamous cell carcinoma of the penis: a report of 3 cases and a review of the literature.

Authors:  Elantholi P Saibishkumar; Juanita Crook; Joan Sweet
Journal:  Can Urol Assoc J       Date:  2008-02       Impact factor: 1.862

6.  [Focal therapy for penile cancer].

Authors:  O W Hakenberg; C Protzel
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

7.  Current and future strategies in the diagnosis and management of penile cancer.

Authors:  Samuel M Lawindy; Alejandro R Rodriguez; Simon Horenblas; Philippe E Spiess
Journal:  Adv Urol       Date:  2011-05-30

8.  Dyadic Aspects of Sexual Well-Being in Men with Laser-Treated Penile Carcinoma.

Authors:  Elisabet Skeppner; Kerstin Fugl-Meyer
Journal:  Sex Med       Date:  2015-06       Impact factor: 2.491

9.  Evaluation of sexual functions and sexual behaviors after penile brachytherapy in men treated for penile carcinoma.

Authors:  Patrice Njomnang Soh; Boris Delaunay; Elie Bou Nasr; Martine Delannes; Michel Soulie; Eric Huyghe
Journal:  Basic Clin Androl       Date:  2014-08-28

10.  Penile cancer brachytherapy HDR mould technique used at the Holycross Cancer Center.

Authors:  Robert Matys; Iwona Kubicka-Mendak; Jarosław Lyczek; Piotr Pawłowski; Iwona Stawiarska; Joanna Miedzinska; Paweł Banatkiewicz; Aldona Laskawska-Wiatr; Justyna Wittych
Journal:  J Contemp Brachytherapy       Date:  2011-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.